Biohaven Ltd. (NYSE:BHVN – Get Free Report) has been given an average rating of “Buy” by the sixteen analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eleven have given a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $48.8462.
BHVN has been the topic of a number of recent analyst reports. UBS Group lowered their target price on Biohaven from $27.00 to $26.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price (down from $54.00) on shares of Biohaven in a research note on Tuesday, August 12th. Bank of America lowered their target price on Biohaven from $50.00 to $49.00 and set a “buy” rating on the stock in a research note on Tuesday, August 12th. Leerink Partners lowered their target price on Biohaven from $60.00 to $50.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th. Finally, Robert W. Baird lowered their target price on Biohaven from $57.00 to $52.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th.
View Our Latest Research Report on Biohaven
Institutional Investors Weigh In On Biohaven
Biohaven Stock Performance
NYSE BHVN opened at $15.84 on Friday. Biohaven has a 1 year low of $12.79 and a 1 year high of $55.70. The company has a debt-to-equity ratio of 1.91, a current ratio of 3.82 and a quick ratio of 3.82. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -2.07 and a beta of 1.03. The company has a fifty day moving average price of $14.81 and a 200-day moving average price of $16.83.
Biohaven (NYSE:BHVN – Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($1.94) EPS for the quarter, hitting analysts’ consensus estimates of ($1.94). As a group, equities research analysts predict that Biohaven will post -8.9 EPS for the current fiscal year.
Biohaven Company Profile
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Read More
- Five stocks we like better than Biohaven
- Find and Profitably Trade Stocks at 52-Week Lows
- Why the Precious Metal Nobody Talks About Could Be Your Best Bet
- Ride Out The Recession With These Dividend KingsĀ
- Cheap Chipotle? Why CMG Stock Could Be Ready for a Comeback
- What Do S&P 500 Stocks Tell Investors About the Market?
- 3 Industrial Stocks Ready to Benefit From Fed Cuts and Spending
Receive News & Ratings for Biohaven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven and related companies with MarketBeat.com's FREE daily email newsletter.